VU0364770

VU0364770 is a selective and potent small molecule positive allosteric modulator (PAM) of the **metabotropic glutamate receptor 4** (mGlu4 or mGluR4), discovered and initially developed by Vanderbilt University. It enhances the action of glutamate at mGlu4 receptors without directly activating the receptor itself. Preclinical models, especially in Parkinson’s disease (PD), show that VU0364770 can reverse haloperidol-induced catalepsy, motor asymmetry, and attentional deficits in rats, and it potentiates the effects of both L-DOPA and adenosine A2A antagonists. This suggests possible "L-DOPA sparing" and adjunctive potential in symptomatic PD treatment. VU0364770 appears to lack intrinsic antidyskinetic effects but may augment dopaminergic therapy in PD[1][3][5][8].

Other names

N-(3-chlorophenyl)picolinamide